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Resubmission of manuscript ALL-2020-00252 as ‘Letter to Editor’
Dear Profs Wang & Akdis,
Many thanks indeed for allowing us the opportunity to resubmit our original ‘Staphylococcus aureus 
internalisation in chronic rhinosinusitis enhances bacterial survival through modulation of host 
immune responses and mast cell activation’ manuscript (ALL-2020-00252) as a ‘Letter to Editor’. 
We apologise for the delay in resubmission due to the Covid pandemic. We have taken on board the 
editorial comments and reformatted the manuscript to comply with the instructions with the 
inclusion of online supplementary material. We have also removed the reference to chronic 
rhinosinusitis as recommended by the reviewers. We have adapted the title accordingly. We believe 
that this process has enhanced and improved the manuscript.
The majority of the data from the original manuscript has been retained. Please see the outline of 
this displayed below. Some of the minor gene and protein data from the original Figure 2 was 
removed. This was in response to the reviewer’s comments and to improve the clarity and 
presentation of the results. We have retained the TNFα gene and protein data, but removed the 
other cytokines as there was no direct comparative gene and protein data available, again in 
accordance with the reviewers’ comments.
 Original Figure 1 - All data retained, now displayed in Figure 1.
 Original Figure 2 - Gene and protein data for TNFα retained, displayed in Figure 1.
 Original Figure 3 - All data retained, now displayed in Figure 2.
 Original Figure 4 - All data retained, now displayed in supplementary Figure 1.
 Original Figure 5 - All data retained, now displayed in Figure 2.
 Original Figure 6 - This illustration is now displayed as supplementary Figure 2.
Thank you again for this opportunity, and look forward to hearing from you in the near future.
Kind Regards,
Rami Salib (on behalf of the authors)































































Staphylococcus aureus internalisation enhances bacterial survival through 
modulation of host immune responses and mast cell activation
To the Editor,
Chronic rhinosinusitis (CRS) is a chronic inflammatory condition of the upper airways affecting up to 
15% of the population, significantly impacting upon patients’ quality of life and resultant healthcare 
resources (1). Whilst the pathophysiological mechanisms underlying CRS are not fully understood, 
Staphylococcus aureus (S aureus) has been shown to play a prominent role (2, 3, 4). In addition to its 
presence on the sinonasal mucosal surface, we previously demonstrated S aureus harbouring within 
mast cells in nasal polyps (2). We revealed that following S aureus intracellular uptake and 
proliferation, bacteria were released into the extracellular space following mast cell rupture, which 
potentially contributed to the repopulation of depleted surface colonies (3). Recent evidence suggests 
that patients with nasal polyps, and especially those with recalcitrant disease, not only have 
intracellular reservoirs of S aureus but also elevated levels of IgE specific to S aureus and their toxins 
(5). Accentuated through their activation via localised anti-S aureus IgE, mast cells should clear 
residual subepithelial bacterial colonies through phagocytosis. It is postulated, however, that S aureus 
may alter the local host immune response to favour its ongoing survival. In the present study we 
investigated mast cell immune response to repeated S aureus internalisation and release cycles and 
further explored the role of IgE in modulating the response of mast cells to S aureus.
The experimental model applied involved cells of the LAD2 mast cell line co-infected with a 
pathogenic CRS S aureus isolate (see supplementary methods section for further details). For the 
study of possible phenotypic mutations altering bacterial immune responses through the sequential 
uptake and release of S aureus from mast cells, additional S aureus populations were created; 
designated C1 (once internalised) through to C5 (five times internalised). S aureus was bound to mast 
cell walls at 2 hours (Figure 1B & C) and internalised between 2 to 4 hours (Figure 1D). Intracellular 































































S aureus were shown to be viable on agar plating (Figure 1E), with no significant difference in the 
number of viable internalised bacteria found between C1 and C5 populations (Figure 1F). Exposure of 
LAD2 mast cells to both the original and C1 population of S aureus was associated with significant 
upregulation of TNFα gene and protein expression (Figures 1G & 1H). Exposure to experienced S 
aureus (C5 population) resulted in downregulated TNFα gene and protein expression (Figures 1G& 
1H). In IgE sensitised and anti-IgE exposed LAD2 cells, there was lower β-hexosaminidase release 4 
hours after the addition of S aureus (Figure 2C). Infection of LAD2 cells with S aureus following IgE 
sensitisation was associated with reduced phosphorylation of AKT2 and glycogen synthase kinase 3 
(GSK-3) α/β (Figures 2F & G), consistent with downregulation of phosphorylation pathways. Figure 
S1 reveals apparent downregulation of TNFα gene expression in S aureus-infected cells following 
IgE-dependent activation.
The key contributions of mast cells in allergic diseases are well established, but there is emerging 
evidence that they also play important roles in a number of chronic bacterial infections, including 
Klebsiella pneumoniae, Mycoplasma pneumonia, Listeria monocytogenes, and most recently S aureus 
in CRS (2, 6). Though mast cells may contribute to clearing infection, S aureus may actually use mast 
cells to evade detection and immune clearance. Using bone-derived murine mast cells and the HMC-1 
line, Abel et al (2011) showed a mast cell response to eradicate S aureus infection through the release 
of pre-formed mediators and extracellular traps (7). However, S aureus was able to subvert these 
killing mechanisms through its internalisation. We have recently shown evidence of S aureus 
surviving within nasal polyp mast cells (2), with S aureus entering through phagocytosis, enhanced in 
the presence of Staphylococcus aureus enterotoxin B (SEB), followed by bacterial proliferation, 
cellular expansion and eventual rupture, with release of viable S aureus into the extracellular space 
propagating ongoing infection (3). This study has shown the ability of a CRS-specific S aureus strain, 
through its release and re-internalisation, to alter its immunogenic phenotype, resulting in a significant 
downregulation of pro-inflammatory cytokine gene expression and release. Modulation of the 
associated host immune response could confer a bacterial survival advantage. Furthermore, results 
also indicate inhibition of maximal degranulation of mast cells upon S aureus internalisation at 4 































































hours. These changes are not unique to S aureus, with mast cells infected with Bifidobacteria, 
Lactobacillus and Escherichia coli showing similar responses (6), although crucially these are non-
pathogenic strains. This could further limit migration of phagocytic cells, thus compromising the 
ability to clear ongoing infection.
The observation of protein kinase phosphorylation gives insights into the possible role of IgE 
sensitisation in S aureus - mast cell interactions. There was reduced protein kinase phosphorylation 
following S aureus infection of IgE-sensitised LAD2 cells, reaching statistical significance for GSK-
3α/β and AKT2. GSK exists in two isoforms (α and β) and regulates the function of over 50 substrates 
involved in various essential cellular functions. GSK-3β inhibition has been shown to suppress 
generation of pro-inflammatory cytokines whilst augmenting production of anti-inflammatory IL-10 
in response to multiple TLR signalling pathways, through NF-κB and CREB interacting with the 
coactivator CREB-binding protein (CBP) (8). Downregulation of GSK-3β phosphorylation has also 
been shown to reduce the pro-inflammatory response, and thereby favour survival of S aureus (9). 
Downregulation of GSK-3β in response to IgE sensitisation and S aureus infection of LAD2 cells 
may constitute a possible route by which S aureus downregulates cytokine production within mast 
cells which have previously been sensitised with anti-S aureus IgE. GSK-3β is therefore potentially 
exploited by pathogenic bacteria as a means of evading the immune system, thus promoting their 
ongoing survival and persistence. 
Our study provides additional insight into the pathophysiology of mast cell function and how S aureus 
can manipulate the cellular environment to favour its own survival. This could manifest clinically 
with treatment resistance and disease recalcitrance. These findings warrant further study, and may be 
relevant in a number of other chronic diseases, including asthma and atopic eczema, where S aureus 
and the generation of S aureus-IgE play a prominent role.
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Figure 1. S aureus is readily internalised by LAD2 mast cells, remaining viable and provoking a 
potent proinflammatory response, which was downregulated upon subsequent bacterial uptake 
and release from mast cells. (A-D) Representative CLSM images of LAD2 mast cells co-cultured 
with a CRS S aureus isolate, with the cell nucleus in blue and cell cytoplasm in red; surface binding S 
aureus (blue arrows) and intracellular S aureus (white arrow) shown. Scale bars in figures 1A-D 
represent 10µm. (E&F) S aureus viability experiments using CFUs. LAD2 mast cells were co-
cultured with a CRS S aureus, C1 and C5 isolate over 4 hours, with TNFα gene expression and 
excreted protein concentration measured (G&H). Data is shown for the mean and SEM of three 
experimental repeats. Paired t-tests were performed, p≤0.05 (*) and p≤0.01 (**).
Figure 2. S aureus inhibits IgE-mediated mast cell activation and inhibits GSK-3 α/β protein 
kinase phosphorylation. The percentage net release of β-hexosaminidase from LAD2 cells was 
measured in the culture supernatant prior to anti-IgE or calcium ionophore stimulation (A) and in 
response to anti-IgE or calcium ionophore stimulation (B-E), with or without IgE sensitisation/S 
aureus infection. Paired t-tests were performed (F) Images for membranes showing phosphorylation 
of 11 main protein kinases in response to sensitisation and infection. (G) Corresponding analysis of 
differences in pixel density within the four groups of cells. Data shown were from a 76 second 
exposure. Images were analysed using Image Lab software. Statistical analysis was performed using 
two-way ANOVA. *(p≤0.05), **(p≤0.01), ***(p≤0.001), ****(p < 0.0001).
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Staphylococcus aureus internalisation enhances bacterial survival through 
modulation of host immune responses and mast cell activation
METHODS
Immortalised cell line (LAD2)
The LAD2 cell line, a kind gift from Dr Cem Akin and Dr Arnold Kirshenbaum, was developed at the 
National Institute of Allergy and Infectious Diseases (NIAID, Rockville, Maryland, USA) from a 
patient with mastocytosis, and represents a more mature mast cell line. LAD2 cells express FcεRI and 
contain granules that degranulate in response to antigen, making them more representative of tissue 
resident mast cells. LAD2 cells were cultured in StemPro-34 SFM media (Life Technologies Ltd, 
Carlsbad, CA, USA) supplemented with stem cell factor (SCF) and 0.2% Gentamycin, Penicillin and 
Streptomycin (Sigma-Aldrich Ltd, Gillingham, UK). 
Bacterial strains and growth conditions
A well phenotyped S aureus isolate was obtained from a CRSwNP patient undergoing surgery at the 
University Hospital Southampton, with written informed consent (ethics approval 07/Q1702/64). The 
isolate was grown to mid-log phase, under static conditions, at 37°C in Roswell Park Memorial 
Institute (RPMI) medium. The optical density (OD600nm) was measured and used to determine the total 
number of viable cells. Bacteria were centrifuged (12,000 g for 10 minutes), washed three times with 
sterile phosphate buffered saline (PBS), and diluted to the required cell number for co-culture, as 
detailed below.
Non-viable, but structurally intact (under microscopy), S aureus was used to investigate whether the 
viability of S aureus altered the immune response. The same strain of S aureus was used and grown to 
the mid-log phase (37°C, 5% CO2) in RPMI medium. S aureus was centrifuged (12,000g for 10 
minutes) and immersed in 16% paraformaldehyde solution for 1 hour. The non-viability of the culture 
was confirmed following lack of growth on colombia blood agar (CBA) plates after 48 hours at 37°C, 
5% CO2.































































Generation of internalised S aureus populations (C1-C5)
LAD2 mast cells (2 x 106) were co-cultured with S aureus at a multiplicity of infection (MOI) ratio of 
1:1 for 4 hours. Co-cultured cells were then centrifuged at 250g for 5 minutes, and the supernatant 
discarded. Cells were washed three times in fresh media, then resuspended in media containing 20 
µg/ml Lysostaphin, and incubated at 37°C for 30 minutes to kill all extracellular S aureus. 
Lysostaphin does not cross the mast cell membrane, thus preserving intracellular S aureus. Following 
treatment, cells were centrifuged at 250 g for 5 minutes, and a CBA plate inoculated with the 
supernatant incubated overnight (37°C, 5% CO2), to confirm the absence of residual extracellular S 
aureus. Cells were then washed three times in fresh media, and vortexed for 10 minutes in 0.5% 
Triton X-100 to release intracellular S aureus. The bacterial suspension was streaked on to a CBA 
plate and incubated overnight (37°C, 5% CO2). S aureus following internalisation by mast cells (and 
now designated C1) was grown to mid-log phase and stored at -80°C in 25% glycerol. This process 
was then repeated with the C1 population, followed by further mast cell internalisation (up to the 5th 
internalisation; C5). All glycerol stocks were stored at -80°C.
S aureus/LAD2 co-culture model
S aureus was grown to the mid-log phase, as detailed above, with the optical density (OD600nm) 
measured, and the number of viable S aureus calculated. S aureus was washed twice and resuspended 
in Hanks' Balanced Salt solution. A known quantity of live and dead S aureus (5 x106 cells) was then 
added to an equal number of LAD2 mast cells (MOI 1:1) over 2 to 24 hours, with and without the 
addition of S aureus Enterotoxin B (SEB, 10µg/ml, Sigma-Aldrich Ltd). Cells were fixed in 2% 
paraformaldehyde solution for confocal imaging, centrifuged with the supernatant stored at -20°C for 
Luminex processing, and the cell pellet stored in RNAlater (Life Technologies Ltd, Carlsbad, CA, 
USA) for real-time quantitative polymerase chain reaction (RT-qPCR).
IgE sensitisation and mast cell activation
LAD2 cells were divided into four different experimental groups (three experimental repeats), each 
containing 5 x 106 cells; no IgE without S aureus, no IgE with S aureus, IgE without S aureus and IgE 































































with S aureus. Sensitised LAD2 cells were exposed to 1.5µg Human Myeloma IgE (Merck Millipore, 
Hertfordshire, UK) over 15 hours, washed three times (250 g for 5 minutes) and resuspend in fresh 
media. 
As previously detailed, S aureus was grown to mid-log phase and co-cultured with infected LAD2 
cell groups at an MOI of 1:1, using 5 x 106 cells and 5 x 106 S aureus per well. Following culture, 
cells were centrifuged (250g for 5 minutes), and split into three groups; no stimulation, anti-IgE 
stimulation and calcium ionophore stimulation. Goat anti-human IgE (Merck Millipore, Hertfordshire, 
UK) at 3 µg/ml (from the study of the immune response) and 10, 3, 1, 0.3, and 0.1 µg/ml (for the β-
hexosaminidase release assays) was added to cells over 2 hours, with calcium ionophore (Sigma-
Aldrich Ltd, Gillingham, UK) groups exposed to 0.03 µg/ml and 0.3 µg/ml of calcium ionophore over 
2 hours. All groups were then centrifuged and stored in RNAlater (Life Technologies Ltd, Carlsbad, 
CA, USA) at -20°C, with RT-qPCR carried out at a later date. Supernatants were snap frozen and 
stored at -80°C. RT-qPCR and Luminex was carried out on cells and supernatant samples as outlined 
below.
Colony forming unit experiments
Mast cells (2 x 106 LAD2 cells) were co-cultured with S aureus at an MOI of 20:1 for 4 hours in 1 ml 
of cell line specific media (37°C, 5% CO2). A higher MOI was chosen for these experiments in order 
to accurately measure smaller volumes of bacteria using the CFU method. Co-culture suspensions 
were centrifuged at 250 g for 5 minutes to pellet the mast cells but retain non-internalised S aureus 
within the supernatant. The supernatant was serially diluted for colony forming unit (CFU) 
enumeration on CBA plates (overnight incubation at 37°C, 5% CO2). Pelleted cells were resuspended 
in media containing 20 µg/ml of Lysostaphin, and incubated at 37°C for 30 minutes to eradicate 
extracellular S aureus (confirmed by plating wash supernatant on CBA plates with overnight 
incubation at 37oC (5% CO2). Cells were then washed three times with fresh media and vortexed for 
10 minutes in 0.5% Triton X-100 to release intracellular bacteria. Samples were then serially diluted 
and CFU enumeration undertaken on CBA plates following overnight incubation (37°C, 5% CO2).































































Real time quantitative polymerase chain reaction 
Cells were thawed on ice, diluted with chilled PBS (4°C) and centrifuged to pellet cells (500 g for 5 
minutes). RT-qPCR was carried out as previously detailed (1), using a TNFα probe (Primerdesign 
Ltd, see Appendix 1) given this is the predominant pro-inflammatory cytokine of the mast cell. 
Measurement of supernatant cytokines
Concentrations of tumour necrosis factor alpha (TNFα) were measured in tissue culture supernatants 
using Luminex® (R&D Systems Inc, Minneapolis, MN, USA), as per the manufacturer’s instructions. 
The plate was analysed on the Luminex analyser (Bio-Plex® 200 System, Bio-Rad Laboratories Ltd, 
Hercules, CA, USA).
Confocal laser scanning microscopy 
Following LAD2 and S aureus culture as detailed above, a 1/200 dilution of a mouse monoclonal anti-
staphylococcus primary antibody (AB37644, Abcam, Cambridge, UK) in PBS with 3% bovine serum 
albumin (BSA) and 0.5% Triton X-100 was incubated overnight at 4°C. Cells were washed three 
times, then incubated at room temperature for 2 hours with a 1/500 dilution of a polyclonal donkey 
anti-mouse Alexa Fluor® 568 (AB175472, Abcam, Cambridge, UK) in PBS with 3% BSA and 0.5% 
Triton X-100. Following further washing steps, cells were incubated in a 25 µM solution of 
CellTracker™ Deep Red fluorescent dye (Life Technologies Ltd, Carlsbad, CA, USA) for 30 minutes. 
Cells were then washed three times with PBS and incubated with 0.5µg/ml of 4',6-diamidino-2-
phenylindole, dihydrochloride (DAPI) with 3% BSA and 0.5% Triton X-100. Cells were then finally 
washed and stored in PBS for imaging. Cells were imaged with a Leica TCS SP8 inverted confocal 
microscope (Leica Microsystems, Milton Keynes, UK) using a 63x glycerol immersion lens. 
Sequential scanning was used to eliminate interference. Images were collected and analysed using 
Leica LAS-AF software.
































































Following culture, with or without S aureus co-infection (for 2 and 4 hours as detailed in the figures), 
LAD2 cells were incubated with anti-IgE at 10, 3, 1, 0.3, and 0.1 µg/ml, calcium ionophore A23817 at 
0.03 µg/ml and 0.3 µg/ml, or with buffer alone (for assessing spontaneous release) at 37°C, with 5% 
CO2 for 2 hours. Total cell-associated β-hexosaminidase content was determined by suspending cells 
in 1% Triton X-100 and agitating vigorously for 2 minutes. Cells were centrifuged (250g, 10 mins), 
and 150 µL of supernatant transferred to a microplate in triplicate. P-nitrophenyl-N-acetyl-β-D-
glucosaminide, a substrate for β-hexosaminidase, was dissolved (130mg) in 0.1 M Na2HPO4, and 
adjusted to a pH of 4.5 with 0.4M citric acid solution, and 50 µl added to each well and incubated for 
1 hour (at 37°C, 5% CO2).  A stop solution (100µL) was added, and the plate read using a Thermo-
max microplate reader (Molecular Devices, Wokingham, UK) at 410 nm wavelength.  Net release of 
β-hexosaminidase with each stimulus (subtracting the level of spontaneous release) was expressed as 
a percentage of total cell-associated β-hexosaminidase.
Protein kinase phosphorylation assay
Phosphorylation of mitogen-activated protein kinases (MAPKs), the extracellular signal-regulated 
kinases (ERK1/2), c-Jun N-terminal kinases (JNK1-3), and different p38 isoforms (α, β, δ, γ) was 
determined using a human Phospho-MAPK array kit (R&D systems Inc) according to the 
manufacturer’s instructions. 
The four sets of cells (non-sensitised non-infected, non-sensitised infected, sensitised non-infected 
and sensitised infected) were prepared as previously outlined, except for using 5 x 106 cells per 
condition within T25 flasks (Fisher Scientific limited, Loughborough, UK). The culture medium was 
adjusted accordingly to 10ml per flask. After overnight IgE sensitisation, cells were infected with S 
aureus over 4 hours. 
Following incubation, cells were harvested and washed (PBS) and then resuspended with 500µl lysis 
buffer 6. The cell lysates were mixed gently by placing on a rocking platform (Stuart Scientific, 
Staffordshire, UK) for 30 minutes at 4°C. Cell supernatants were collected following centrifugation 































































(14,000g, 5 minutes) and transferred to new tubes, which were stored at -80°C until assay was 
completed. 
Statistics
Statistical analysis was performed using Graph Pad Prism 7.0 software (Graph Pad Software Inc., San 
Diego, CA, USA). Paired and unpaired t-tests were undertaken, and where appropriate one-way and 
two-way ANOVA, with multi-parametric analysis, as detailed in individual figure legends.
Study approval
All methods were carried out in accordance with relevant guidelines and regulations. All experimental 
protocols were approved by the Southampton and South West Hampshire Research Ethics Committee 
(ref - 09/H0501/74). Informed written consent was obtained from all participants prior to inclusion in 
the study. Relevant non-infected control samples were used for all experimental techniques as a 
means of validating observed trends.
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Figure S1 - Upon initiation of the IgE signalling pathway, S aureus infected mast cells revealed 
significant downregulation of TNFα gene expression. Cells stimulated with or without IgE and/or 
co-infected with S aureus. IgE stimulation was performed overnight, with S aureus infection (MOI 
1:1) undertaken over 4 hours. Following culture samples underwent 3µg/ml anti-IgE stimulation (A & 
B), no further stimulation (C&D), or 0.03µM calcium ionophore stimulation (E&F). Data is shown 
for three experimental repeats, with boxes representing the 25th to 75th percentile, and whiskers 
representing the 5th to 95th percentile. Two-way ANOVA was undertaken, p≤0.05 (*).
Figure S2 - Proposed illustrated model of Staphylococcus aureus survival in CRS.
































































RT-qPCR primer sequences 
RT-qPCR Housekeeping gene amplicon context information 
Human ACTB:
Accession number: NM_001101
Anchor Nucleotide position: 1195
Context sequence length: 106bp
Gene name Manufacturer Sense primer Anti-sense primer
TNFα Primerdesign CCAGGGACCTCTCTCTAATCA TGCTACAACATGGGCTACAG
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